SKLB325

SKLB325

S661696-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

SKLB325 is a Jumonji domain-containing 6 ( JMJD6 ) inhibitor with a binding affinity ( K D ) value of 0.755 μM, and the IC 50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SK In Vitro:SKLB325 suppresses ovarian cancer growth through inhibition of proliferation and induction of apoptosis and cell death, and inhibiting angiogenesis may play a significant role in inhibiting tumor growth. SKLB325 (0.25-16 μM; for 24-72 h) has signific In Vivo:SKLB325 (10mg/kg) has antitumor activities in an intraperitoneal xenograft model. SKLB325 significantly prolongs the survival of tumor-bearing mice without obvious side effects. SKLB325 treatment protocols were effective in suppressing SKOV3, ES2, CP70, Biological Activity:SKLB325 is a Jumonji domain-containing 6 ( JMJD6 ) inhibitor with a binding affinity ( K D ) value of 0.755u2009μM, and the IC 50 value of 0.7797u2009μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis

C12H12N4O2

244.25 g/mol

OC1=NC(N/N=C/C2=CC=CC=C2O)=NC(C)=C1